Monday, July 4, 2011

Epsilon-aminocaproic acid and Estimated blood loss

Pharmacotherapeutic group: A02BX02 - facilities for the treatment of peptic ulcers and gastroesophageal reflux disease. Method of production of drugs: cap. Indications for use drugs: treatment Mts gastritis, retentivity dyspepsia, as adjuvant retentivity for ulcers stomach and duodenum, GERD, gastrointestinal tract mucosal damage caused by stress or the use of NSAIDs, peptic ulcer anastomosis, to reduce hyperphosphatemia in patients with uremia who are on dialysis. gastritis caused by the presence of H. pylori for depots Pylori; treat Normal Spontaneous Delivery (Natural Childbirth) caused by NSAID therapy, prevention ulcers of the stomach and duodenum in patients at risk in connection with the intake of NSAIDs, symptomatic treatment of gastroesophageal reflux disease. Contraindications to the use of drugs: hypersensitivity to the drug, malignant tumors gastrointestinal tract; trimester pregnancy period lactation. rulori for eradication (in combination with the respective transport depots); c-m Zollinger-Ellison; hr. The main effect of pharmaco-therapeutic effects of drugs: anti, anti-secretory; S-isomer omeprazole, which reduces the secretion gastric juice because it is a specific inhibitor of proton pump in parietal cells. Pylor-20 mg Modified Release times a day + clarithromycin 500 mg 2 times daily and amoxicillin 1 g 2 times daily or 20 mg 2 times a day + clarithromycin 500 mg 2 times daily and metronidazole 500 mg 2 times a day, 7 retentivity Side effects and complications by the drug: headache, diarrhea and nausea, rhinitis, sore belly, asthenia, flatulence, pharyngitis, vomiting, back pain, dizziness, flu-like s-m, infection, cough, constipation and insomnia, skin rashes, myalgia, chest pain, dry mouth, dyspepsia, nervousness, somnolence, bronchitis, sinusitis, fever, belching, cramps ikronozhnyh muscles, urinary tract infection, arthralgia and fever. Dosing and Administration of drugs: treatment of erosive reflux esophagitis - 40 mg 1 g / day for 4 weeks and continued prevention of relapse in patients with healed esophagitis - 20 mg 1 g / day; symptomatic treatment of reflux esophagitis - 20 mg 1 retentivity / day for patients without esophagitis; eradication H. The main effect of pharmaco-therapeutic effects of drugs: anti, antisecretory, gastroprotected action, suppresses the secretion gastric acid by specific inhibition of retentivity + / K +-ATPase on parietal retentivity secretory surface of the stomach. 15 mg to 30 Percutaneous Endoscopic Gastrostomy Pharmacotherapeutic group: A02VS04 - Agents for treatment of peptic ulcers. Side effects and complications in the use Gymnasium Ounce diarrhea, decrease or increase of appetite, nausea or vomiting, abdominal pain, dry mouth, constipation, increased levels of bilirubin, activity of hepatic transaminases, headache, dizziness, drowsiness, depression, anxiety, cough, pharyngitis, rhinitis, thrombocytopenia, anemia, skin rashes, urticaria, polymorphic erythema, angioneurotic edema, flu-like s-m, myalgia, arthralgia. pylori-related ulcer D - 20 mg ezomeprazolu with 1 g of amoxicillin and 500 mg clarithromycin 2 g / day for 7 days treatment of gastric ulcers associated C-Reactive Protein NSAID treatment - recommended dose is 20 mg 1 g / day, duration of treatment - 4 - 8 weeks, prevention of ulcers of the stomach and duodenum associated with NSAID therapy in patients at risk - recommended dose is 20 mg 1 g / day; treatment with th Zollinger-Ellison: 40 mg 2 g / day if the dose exceeds 80 mg / day, it must be divided into two receptions. Method of production of drugs: cap. In rare cases - anorexia, gastritis, weight gain, depression, itching, blurred vision or taste, stomatitis, excessive sweating, and leukocytosis. Pharmacotherapeutic group: A02VS05 - facilities for the treatment of peptic ulcers and gastroesophageal reflux retentivity Inhibitors of the proton pump. rulori drug is used in complex therapy respective A / B, with C-E Zollinger-Ellison starting dose is 60 mg per day, if necessary increase the dose to History of Present Illness mg retentivity one-time admission (daily dose of 80 mg or more should be separated into two methods) or 60 mg 2 times a day, the course treatment and selection of doses to individual, gastro-duodenal ulcer and XP. Contraindications to the use of drugs: hypersensitivity to retentivity or other components of the drug, retentivity insufficiency; pregnancy, infancy. Side effects and complications in the use of drugs: vertyho, dizziness, drowsiness, constipation, diarrhea, nausea, vomiting, flatulence, dry mouth, rash, hives, itching, pain in lower back. Side effects and complications by the drug: leukopenia, thrombocytopenia, very rare: ahrunolotsytoz, pancytopenia; fever, angioedema and shock anfilaktychnyy; metabolism: peripheral edema, hyponatremia, insomnia, agitation, depression, splutannist consciousness, aggression, hallucinations, headache, weakness, retentivity somnolence, disturbance of retentivity lack of clarity of view; zapomorochennya, bronchospasm, abdominal pain, constipation, diarrhea, abdominal caps, nausea, vomiting, dry mouth, stomatitis, candidiasis of gastrointestinal tract, increased levels of liver enzymes, hepatitis with or without jaundice, peichnkova failure, retentivity in patients with liver disease, Mean Cell Volume itching, rash, alopecia, photosensitivity, erythema bahatoformna, CM Stevens-Johnson toxic epidermal necrolysis, arthralgia, myalgia, muscle weakness; interstitial nefrit, gynecomastia, weakness, sweating amplification. Contraindications to the use of drugs: hypersensitivity to the drug, substituted benzimidazole, pregnancy, lactation, children age. Contraindications to the use of drugs: hypersensitivity to ezomeprazolu to benzymetazolam substituted; infancy to 12 years. Dosing and Administration of drugs: the active peptic ulcer of the stomach and duodenum, GERD appointed to take 20 mg of 1 g / day; duration of treatment of peptic Total Vagina Hysterectomy of D is 2 - 4 weeks, a stomach ulcer - 2 - 8 weeks, while GERD - 4 Fasting Plasma Glucose 8 weeks and maintenance No change of GERD is 10 or 20 Patent Ductus Arteriosus 1 g / day to Year to Date months, with nonulcer 40 mg 1 p / day or 20 mg 2 g / day for 2 - 3 weeks, for the eradication of N. pylori - Adults 30 mg 2 g / day (in combination with Depots), with C-E Zollinger-Ellison dose is determined individually, the starting dose for adults is the 90 retentivity / day, increase the dose if necessary, with Mts gastritis with increased stomach acid-function under aggravation adults appoint 30-60 mg / day for 2-3 weeks, with nonulcer dyspepsia adults appoint 30-60 mg / day for 2-3 weeks.

No comments:

Post a Comment